Meeting
2023 ASCO Annual Meeting
Additional prognostic value of the BCT score in patients with ER+HER2- breast cancer receiving 21-gene assay–guided adjuvant treatments.
Authors
Sung Gwe Ahn
Gangnam Severance Hospital, Yonesi University, Gangnam-Gu, NA, Korea, Republic of (South)
Sung Gwe Ahn , Yoonwon Kook , Sae Byul Lee , Eun-Gyeong Lee , Jonghan Yu , Young-Won Lee , Yeon Jin Kim , Sang Uk Woo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 548)
DOI
10.1200/JCO.2023.41.16_suppl.548
Abstract #
548
Poster Bd #
378
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
An analysis of breast cancer index scores predicting benefit of extended endocrine therapy by race.
First Author: Nicholas Siu-Li
Poster
2018 ASCO Annual Meeting
Molecular alterations and late recurrence in postmenopausal women with hormone receptor-positive node-positive breast cancer (BC): Results from the “SOLE” trial.
First Author: Elena Guerini Rocco
Poster
2015 ASCO Annual Meeting
Prediction of late distant recurrence (DR) using the Prosigna (PAM50) test in a Danish Breast Cancer Cooperative Group (DBCG) cohort of postmenopausal women diagnosed with hormone receptor-positive (HR+) early breast cancer (EBC) allocated to 5yr of endocrine therapy (ET).
First Author: Anne-Vibeke Lænkholm
Poster
2015 ASCO Annual Meeting
Prediction of 10yr distant recurrence (DR) using the Prosigna (PAM50) assay in a Danish Breast Cancer Cooperative Group (DBCG) cohort of postmenopausal Danish women with hormone receptor-positive (HR+) early breast cancer (EBC) allocated to 5yr of endocrine therapy (ET) alone.
First Author: Anne-Vibeke Lænkholm